Jefferies Financial Group Increases AstraZeneca (LON:AZN) Price Target to GBX 74

AstraZeneca (LON:AZN) had its price target raised by stock analysts at Jefferies Financial Group from GBX 71 ($0.90) to GBX 74 ($0.94) in a research report issued on Tuesday, MarketBeat Ratings reports. The firm presently has a “hold” rating on the biopharmaceutical company’s stock. Jefferies Financial Group’s price target points to a potential downside of 99.38% from the stock’s current price.

A number of other equities research analysts have also recently commented on AZN. JPMorgan Chase & Co. restated an “overweight” rating on shares of AstraZeneca in a research report on Tuesday, June 4th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and issued a £110 ($139.13) price target on shares of AstraZeneca in a research note on Tuesday, June 18th. Berenberg Bank raised their target price on shares of AstraZeneca from £130 ($164.43) to £150 ($189.73) and gave the stock a “buy” rating in a research note on Friday, June 7th. Barclays reaffirmed an “overweight” rating and set a £125 ($158.11) price target on shares of AstraZeneca in a research report on Monday, April 8th. Finally, Shore Capital reiterated a “buy” rating on shares of AstraZeneca in a report on Tuesday, May 21st. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, AstraZeneca has a consensus rating of “Moderate Buy” and a consensus price target of £105.53 ($133.49).

AstraZeneca Price Performance

Shares of AZN opened at £120.20 ($152.04) on Tuesday. The business’s 50-day moving average is £122.69 and its two-hundred day moving average is £111.07. The company has a market capitalization of £186.31 billion, a P/E ratio of 3,848.72, a P/E/G ratio of 0.97 and a beta of 0.16. The company has a debt-to-equity ratio of 92.51, a quick ratio of 0.59 and a current ratio of 0.89. AstraZeneca has a fifty-two week low of GBX 9,461 ($119.67) and a fifty-two week high of £127.04 ($160.69).

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.